Similarly, SS31, a mitochondria-targeted antioxidant peptide, has been shown to inhibit NLRP3 inflammasome activation and pyroptosis by regulating S100A8, offering a novel therapeutic approach to mitigate LPS-induced ALI (Luo et al., 2024). Here, NLRP3 is linked to acute respiratory distress syndrome.